Medpace Holdings Inc
F:01P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Medpace Holdings Inc
F:01P
|
US |
Medpace Holdings Inc
Medpace Holdings is a contract research company that helps drug and medical device makers run clinical trials. It designs study plans, manages sites and patients, collects trial data, and handles the regulatory and operational work needed to test new treatments. Its customers are mainly biopharma companies, biotech startups, and medical device firms that need outside expertise to get products through development. The company makes money by charging clients for these research services, usually under project-based contracts tied to specific trials and milestones. Rather than selling a drug or device itself, Medpace sits in the middle of the development process and earns fees for coordinating the work from early trial planning through final data analysis. That makes its business closely linked to the pace of new product development in life sciences. What sets Medpace apart is its focus on full-service clinical development. It does not just provide lab testing or isolated support; it runs many parts of the trial process for customers that want one partner to manage the complex details. For beginners, the key idea is simple: Medpace helps life sciences companies turn a promising idea into a tested product by taking on the hardest parts of clinical research.
Medpace Holdings is a contract research company that helps drug and medical device makers run clinical trials. It designs study plans, manages sites and patients, collects trial data, and handles the regulatory and operational work needed to test new treatments. Its customers are mainly biopharma companies, biotech startups, and medical device firms that need outside expertise to get products through development.
The company makes money by charging clients for these research services, usually under project-based contracts tied to specific trials and milestones. Rather than selling a drug or device itself, Medpace sits in the middle of the development process and earns fees for coordinating the work from early trial planning through final data analysis. That makes its business closely linked to the pace of new product development in life sciences.
What sets Medpace apart is its focus on full-service clinical development. It does not just provide lab testing or isolated support; it runs many parts of the trial process for customers that want one partner to manage the complex details. For beginners, the key idea is simple: Medpace helps life sciences companies turn a promising idea into a tested product by taking on the hardest parts of clinical research.
Revenue: Medpace reported first-quarter revenue of $706.6 million, up 26.5% year over year, with EBITDA and earnings also up, but not as fast as revenue because of a higher tax rate.
Bookings pressure: Net new awards were $618.4 million and net book-to-bill was 0.88, held back by cancellations that rose to their highest level in over a year and by weaker gross bookings.
Outlook unchanged: Management kept 2026 guidance unchanged, saying revenue and profit ranges still look achievable despite the first-quarter booking headwind.
Cancellation mix: Management said the higher cancellations were mostly ordinary project-specific issues such as product performance and reprioritizations, not acute funding stress or M&A.
Growth concern: August Troendle said the company’s sequential growth profile is now a real concern unless cancellations ease or gross awards improve, and he expects the team to keep pushing win rates and pipeline growth.
Capital allocation: Medpace said it still has more than $800 million of share repurchase authorization and will continue to execute on its buyback strategy.
